Sign In
Buy CRSP
$47.78
-0.790 (-1.63%)
At Close: Jul 17, 2026
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
06:51pm, Friday, 17'th Jul 2026
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
07:01pm, Thursday, 16'th Jul 2026
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 14'th Jul 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
06:51pm, Friday, 10'th Jul 2026
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
3 Reasons to Buy CRISPR Therapeutics Stock
01:00pm, Friday, 10'th Jul 2026
CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
05:45am, Wednesday, 08'th Jul 2026
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
07:01pm, Tuesday, 07'th Jul 2026
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
01:45pm, Tuesday, 07'th Jul 2026
CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.
Progress Report: How Our Top Stock Picks of 2026 Are Faring
01:05pm, Tuesday, 07'th Jul 2026
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
10:36am, Tuesday, 07'th Jul 2026
CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market wi
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:35am, Monday, 06'th Jul 2026
CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding
CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices
05:05pm, Friday, 03'rd Jul 2026
CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.
Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment
12:14pm, Friday, 03'rd Jul 2026
Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
08:37am, Friday, 03'rd Jul 2026
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:01am, Tuesday, 30'th Jun 2026
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
